

Patient experience of participation within the CAIN trial, a phase 1 clinical trial evaluating the effectiveness and safety profile of the HistoSonics Histotripsy System in treating primary solid renal tumours.

Brandon J, Zhong J, Wah T M

Leeds Teaching Hospitals NHS Trust

Purpose: The CAIN trial successfully delivered the global-first translation of histotripsy technology in renal cancer treatment (Leeds Teaching Hospitals NHS Trust, 2023). The aim of this patient-focused study was to gather insights into the participants' experience.

Material and Methods: The UK National Institute of Health Research (NIHR) Participant in Research Experience Survey (PRES) was provided to all participants treated between 01/03/2023-01/11/2024. Completion of the survey was voluntary, and responses anonymised. Data were extracted to measure demographics, Likert scale responses of research experience and free-text comments.

Results: All study participants (n=8) responded. Demographics: All white British ethnicity, female/male (2/6), Age groups [60-69 (n=2), 70-79 (n=3), 80-89 (n=1), non-stated (n=2)]. All participants stated this was the first research trial they had participated in. All agreed (n=2) or strongly agreed (n=6) they would take part in research again. All agreed (n=1) or strongly agreed (n=7) they felt well prepared for the trial by the information provided in advance. All agreed (n=2) or strongly agreed (n=6) they felt their participation had been valued. All agreed (n=2) or strongly agreed (n=6) they had been treated with courtesy and respect. Participants' free-text comments identified key themes of altruism, and the desire to contribute to medical science and the development of future treatments and technologies.

Conclusion: Participants were prepared to try novel therapy despite absence of long-term data, with high levels of motivation to help others and future technologies. High levels of satisfaction were reported for participating in this early-phase innovative, novel trial treatment, with willingness to participate in future trials.

References:

Leeds Teaching Hospitals NHS Trust (2023). Leeds Teaching Hospitals NHS Trust (UK) Performs World First Non-Invasive Histotripsy in Patient with Primary Solid Renal Tumor [Online] available at: <https://www.leedsth.nhs.uk/news/leeds-teaching-hospitals-nhs-trust-uk-performs-world-first-non-invasive-histotripsy-in-patient-with-primary-solid-renal-tumor/#:~:text=The%20CAIN%20trial%20represents%20a,for%20kidney%20cancer%20treatment%20generally.> [accessed 05/02/2025]